PPI Test in GP Patients

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the diagnostic value of two week treatment with Nexium as a confirmatory test for patients with suspected reflux disease.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Collaborator: UMC Utrecht
• Treatments: Esomeprazole

Criteria

Inclusion Criteria:

• Age ≥ 18 years

• Symptoms suggestive for gastric acid reflux disease during 2 or more days per week

Exclusion Criteria:

• Treatment with prokinetic or acid secretion inhibitors within 4 weeks prior to inclusion

• Treatment with a PPI for more than 30 days within the last 3 months prior to inclusion

• History of proven peptic ulcer disease, unless successfully treated with Helicobacter pylori eradication longer than 1 month before inclusion